The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

(Reuters) -Shares in global vaccine makers and drugmakers fell on Friday after U.S. President-elect Donald Trump picked ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

Manila Water Foundation Joins Erceflora Probiotics and Save the Children Philippines to Expand Hygiene and Water Access for ...

If confirmed as the HHS Secretary by the US Senate, RFK Jr will oversee federal agencies that dictate healthcare policy in ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

London-listed GSK Plc and France’s Sanofi SA saw similar declines ... Centers for Medicare and Medicaid Services and the Food ...

Trump announced Thursday he’ll nominate Robert F. Kennedy Jr. to be secretary of the Health and Human Services Department after […] ...

FRANKFURT: European shares slipped on Friday, weighed down by disappointing earnings, concerns about the impact of ...